Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Investor Presentation (May 2023)
18 slides from Rockwell Medical's investor presentation, May 15, 2023
Slide 1: Investor Presentation
Investor Presentation May 15, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell’s expectations regarding revenue, profitability, financial position, reliance on capital investments,
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance • Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide Business • Second largest supplier of acid and bicarbonate concentrates for dialysis patients in the U.S. Overview • Re
Slide 4: Executive Management Team
Executive Management Team Mark Strobeck, Ph.D. Paul E. McGarry, CPA Megan Timmins President and CEO SVP, Finance and EVP, Chief Legal Chief Accounting Officer Officer and Secretary Tim T. Chole Marc Hoffman, M.D. Heather R. Hunter SVP, Sales and Marketing SVP, Chief Medical Officer SVP, Chief Corpor
Slide 5: Corporate Strategy
Corporate Strategy q Be the Global Leader in Hemodialysis Concentrates q Provide Customers with the Highest Quality and Most Reliable Products and Services q Achieve Profitability and $100M+ Annual Revenue q Focus on Innovative, Long-Term Growth Opportunities 5 © 2023 Rockwell Medical, Inc.
Slide 6: What is Hemodialysis?
What is Hemodialysis? • Procedure whereby a dialysis machine and a special filter called an artificial kidney — or dialyzer — are used to clean a patient’s blood. • Filters out wastes, salts, and excess fluid, and corrects electrolyte and acid-base imbalances for people who have kidney failure, or e
Slide 7: U.S. In-Center Hemodialysis Concentrates Market
U.S. In-Center Hemodialysis Concentrates Market Estimated growth driven primarily by increasing number of patients suffering from end-stage kidney disease $380M $500M TODAY 2026 SOURCE: “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) 7 © 2023 Rockwell Medical, I
Slide 8: Indispensable Player in a Large and Expanding Market
Indispensable Player in a Large and Expanding Market • Rockwell Medical currently serves 1700+ dialysis clinics and growing. • Rockwell Medical is one of two manufacturers and suppliers that has scalability and transportation infrastructure to service the 7,200+ dialysis clinics in the U.S., along w
Slide 9: Potential Growth Opportunities and Revenue Streams
Potential Growth Opportunities and Revenue Streams Geographic Complementary Market Expansion Products Consolidation • To-date, Rockwell has been • Expand product opportunities geographically concentrated • Hemodialysis Market ripe • Leverage domain expertise in in the East, South, Midwest for Consol
Slide 10: International Partnerships
International Partnerships 10
Slide 11: Ferric Pyrophosphate Citrate (FPC) Platform
Ferric Pyrophosphate Citrate (FPC) Platform Indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis- dependent chronic kidney disease Bypasses the liver, delivers iron directly to circulating transferrin1 TRIFERIC Internationally • Expect royalties from our s
Slide 12: FPC Development Pipeline
FPC Development Pipeline Preclinical Phase 1 Phase 2 Phase 3 Submitted Approved Commercial Partners Hb Maintenance in Dialysis Patients TRIFERIC® (Dialysate) Korea TRIFERIC® AVNU (I.V.) Korea TRIFERIC® AVNU (I.V.) Turkey TRIFERIC® AVNU (I.V.) China TRIFERIC® AVNU (I.V.) India Development work on Hol
Slide 13: Financials and Milestones
Financials and Milestones 13
Slide 14: Delivering on New Business Strategy
Delivering on New Business Strategy Highest quarterly revenue to-date, improved financial performance Three Months Ended March 31 (In Thousands, Except Per Share Amounts) 2023 2022 Net Sales $ 19,668 $ 16,124 Gross Profit (Loss) $ 2,599 $ (786) Operating Loss $ (1,427) $ (6,626) Net Loss $ (1,750) $
Slide 15: Focused on Driving Business to Profitability in 2024
Focused on Driving Business to Profitability in 2024 … along with revenue growth, reducing expenses and paying down debt Revenue Gross Profit (Loss) Debt* ($M) ($M) 10 85 9 7.0 - 9.0 ($M) 78.0 – 82.0 8 21.6 80 7 20 6 5 4.1 75 4 15 72.8 3 10.0 2 10 8.0 70 (2.4) 1 0 -1 5 65 2.0 61.9 -2 0 -3 0 60 2021
Slide 16: Projected Milestones for 2023
Projected Milestones for 2023 q Complete 100% Transfer of Baxter Business with Preferred Economics q Expand Partnerships with Existing Hemodialysis Customers q Grow Concentrates Business by Adding New Customers q Distribute Hemodialysis Products in New Geographies q Increase TRIFERIC® Sales in Korea
Slide 17: Why Invest in Rockwell Medical?
Why Invest in Rockwell Medical? q Revenue-Generating Business q Large and Growing Market Opportunity q Path to Profitability in 2024 q Strengthened Financial Position q Attractive Valuation 17 © 2023 Rockwell Medical, Inc.
Slide 18: www.rockwellmed.com
www.rockwellmed.com 18 IR@rockwellmed.com